Walleye Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Walleye Capital’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-143,293	Closed	-$5.91M	–	4685
2025 Q4	$5.91M	Sell	143,293 -269,793	-65%	-$10.8M	0.02%	1016
2025 Q3	$16M	Buy	413,086 +293,201	+245%	+$9.53M	0.06%	331
2025 Q2	$3.32M	Buy	119,885 +33,682	+39%	+$857K	0.01%	1138
2025 Q1	$1.91M	Buy	+86,203	New	+$1.77M	0.01%	1453
2024 Q1	–	Sell	-327,332	Closed	-$5.74M	–	5645
2023 Q4	$5.74M	Buy	+327,332	New	+$5.38M	0.01%	1016
2023 Q1	–	Sell	-48,217	Closed	-$722K	–	4166
2022 Q4	$722K	Sell	48,217 -175,018	-78%	-$2.55M	0.01%	1206
2022 Q3	$2.87M	Sell	223,235 -72,688	-25%	-$828K	0.05%	389
2022 Q2	$2.87M	Buy	295,923 +194,313	+191%	+$1.81M	0.08%	275
2022 Q1	$1.01M	Buy	101,610 +18,246	+22%	+$193K	0.03%	631
2021 Q4	$981K	Buy	+83,364	New	+$1.02M	0.03%	606

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Walleye Capital's KNSA Position: Q1 2026 in Review

Walleye Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 143,293 shares — an estimated $5.91M sold.

Walleye Capital first reported a position in KNSA in Q4 2021 and held it in 10 quarters. The position peaked at $16M in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Walleye Capital reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 143,293 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $5.91M.
Walleye Capital first reported a position in Kiniksa Pharmaceuticals in Q4 2021 and held it in 10 quarters.
Walleye Capital's Kiniksa Pharmaceuticals position peaked at $16M in Q3 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.